Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.43 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 2/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9995253 | 0.80 | GSR (0.40) | KMT2AMEN1POLBCYP1A2 | |
| SCHEMBL15856901 | 0.79 | ESR1 (0.61) | KMT2AMEN1POLBALDH3A1HTT | |
| SCHEMBL7168183 | 0.77 | NOS2 (0.53) | KMT2AMEN1NOS2POLBNOD1 | |
| SCHEMBL1384105 | 0.77 | RPS6KB1 (0.70) | HTTTP53 | |
| SCHEMBL2309144 | 0.77 | MAPK1 (0.61) | KMT2AMEN1NOS2POLBNOD1 | |
| SCHEMBL21568779 | 0.77 | KMT2A (0.45) | KMT2AMEN1POLBHTTESR1 | |
| Hydrochloric Acid SCHEMBL7167676 | 0.76 | NOS2 (0.52) | KMT2AMEN1NOS2POLBHTT | |
| SCHEMBL15214855 | 0.74 | L3MBTL1 (0.56) | KMT2AMEN1NOS2POLBNOD1 | |
| SCHEMBL7294918 | 0.74 | NOS2 (0.50) | KMT2AMEN1NOS2POLBNOD1 | |
| SCHEMBL5945572 | 0.74 | ESR1 (0.54) | KMT2AMEN1NOS2POLBNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582680-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | Novartis AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | disclosed |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | disclosed |
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | disclosed |
| WO-2011157787-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157787-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090342-A1 | BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | IGF1R, IGFBP1, IGFBP2 | KMT2A 1942/4885MEN1 747/4885NOS2 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.